Genome

Korea University Study Explores a Novel and Precise Mitochondrial Gene Editing Method

Retrieved on: 
Friday, February 23, 2024
Toxicity, Gene editing, File association, DSM-IV codes, DNA replication, Cell, RNA, Associate, Genome, A-DNA, Issue 1, Research, DNA, Mouse, Korea University, Vaccine

Targeted base editing of mammalian mtDNA is a powerful technology for modeling mitochondrial genetic diseases and developing potential therapies.

Key Points: 
  • Targeted base editing of mammalian mtDNA is a powerful technology for modeling mitochondrial genetic diseases and developing potential therapies.
  • Programmable deaminases, which consist of a custom DNA-binding protein and a nucleobase deaminase, enable precise mtDNA editing.
  • Prof. Lee's research hints at a potential future in which the mitochondrial gene editing technology gains similar recognition.
  • The achievement of correcting mitochondrial A-to-G in mice not only highlights the efficacy of the novel gene editing method but also signals a significant step toward developing approved treatments for mitochondrial genetic diseases.

PUER Joins Campden Wealth As a Corporate Partner to Provide Multigenerational Health Resources

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Education, Cholesterol, Physician, Molecular medicine, FAHA, Drug development, System, Health, Therapy, UHNW, Genome, FACC, Genomics, Trial of the century, Management

ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.

Key Points: 
  • ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.
  • PUER is joining the Campden Wealth community as one of Campden Wealth's select corporate partners for 2024.
  • PUER offers a high-touch, high-science, multigenerational concierge program with the most comprehensive health planning for families.
  • A centennial time horizon aims to complement multigenerational family education and resources facilitated by Campden Wealth.

Genomenon to Detail Gene Curation Across the Clinical Exome in Scientific Presentation at 2024 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Wednesday, February 21, 2024
VUS, ANN, Virginia High School League, ACMG, Genome, Medicine, Gene, Genomics, Diagnosis, CALM1, Vaccine

ANN ARBOR, Mich., Feb. 21, 2024 /PRNewswire-PRWeb/ -- Genomenon, a leading genomic intelligence company, will deliver a scientific presentation, present two posters, and host a showcase presentation at the ACMG Annual Clinical Genetics Meeting being held in Toronto, Canada, March 12-16, 2024.

Key Points: 
  • ANN ARBOR, Mich., Feb. 21, 2024 /PRNewswire-PRWeb/ -- Genomenon, a leading genomic intelligence company, will deliver a scientific presentation, present two posters, and host a showcase presentation at the ACMG Annual Clinical Genetics Meeting being held in Toronto, Canada, March 12-16, 2024.
  • The scientific presentation will describe the company's initiative to curate and fully characterize gene-disease relationships (GDRs) across all genes associated with the clinical exome using a gene-first approach facilitated by computational indexing of published evidence to ensure maximal sensitivity.
  • The importance of systematic identification of all published variants and expert review of associated evidence will be highlighted.
  • This effort is critical for resolution of variants of uncertain significance (VUS) and will enable more rapid and accurate variant interpretation.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

From crop to cup – a new genetic map could make your morning coffee more climate resilient

Retrieved on: 
Wednesday, February 14, 2024
Incidence, USD, Arabica, Animal, Farmer, Plant, Genetic code, Parent, Coffee, Climate change, University, Chromosome, Human, Genetics, Coffea, Genome, Family, Medicine, Heterosis, Disease resistance, Breeding, DNA, Caledonia

With their superior smooth taste and many fine varieties, arabica coffee beans make up around 60%-70% of global coffee production.

Key Points: 
  • With their superior smooth taste and many fine varieties, arabica coffee beans make up around 60%-70% of global coffee production.
  • Coffee cultivation also directly supports the livelihoods of 25 million family farmers with another 100 million people involved in coffee processing and retailing.
  • This study could help produce coffee varieties with higher yields and more resilience to climate change.
  • With more detailed information about the genetic makeup of coffee, researchers can begin to use these methods to improve coffee varieties.

Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller

Retrieved on: 
Wednesday, February 14, 2024
Retinitis pigmentosa, Cataract, CRISPR, Usher, Growth, Genome, University, Therapy, DSM-IV codes, Family, Medicine, Oxidative stress, Usher syndrome, Research, Pharmaceutical industry

FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the expansion of its business advisory board with the appointment of Daniel Feller.

Key Points: 
  • FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the expansion of its business advisory board with the appointment of Daniel Feller.
  • Mr. Feller founded Talisman Licensing, a brand building agency in Melbourne, Australia, and has served as its CEO since the Company’s inception in 2007.
  • Mrs. Feller also co-founded and currently serves as the director of UsherKids Australia, an Australian-based support network for families with children diagnosed with Usher syndrome.
  • “Nacuity’s oxidative stress therapies have broad potential to treat a variety of diseases, including retinitis pigmentosa associated with Usher syndrome.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, Other Health, Technology, Stem Cells, Pharmaceutical, Surgery, Medical Devices, Genetics, Clinical Trials, Biotechnology, Science, Software, Veterinary, Other Science, Research, Health, Meiji University, Embryology, Cell, Doctor of Philosophy, Coagulation, Inflammation, Quality of life, Pelvic floor dysfunction, Transgene, Transplant, Genome, Patient, Gene, Kidney, Mortality, Tissue, Vaccine

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Genetics, Health, Agilent Technologies, BGI Group, Genetic disorder, Magnis, Illumina, Inc., DSM-IV codes, Genetic variation, Liquid biopsy, QIAGEN, Genomics, NGS, Marker beacon, Thermo Fisher Scientific, BGI, Fertilisation, Noninvasive prenatal testing, Genome, Informatics, CTC, Research, DNA, Medical device

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

Global Genome Editing Market Research Report 2023-2035: Pharmaceutical Giants Expand Capabilities - WuXi AppTec and Ensoma Lead Acquisitions - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Health, Genetics, Acquisition, Wuxi, Regenerative medicine, CRISPR, WuXi AppTec, Gene editing, Intellia Therapeutics, Research, Cas9, Drug discovery, Mammoth Biosciences, Genetic engineering, Safety, Therapy, Genome, Horizon Discovery, Genomics, Antibiotics

The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).